

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	ARGENICA THERAPEUTICS LIMITED
ABN	38 620 388 230

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	LIZ DALLIMORE
Date of last notice	30 NOVEMBER 2022

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	INDIRECT
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	TRUSTEE AND BENEFICIARY
Date of change	8 AUGUST 2024
No. of securities held prior to change	MRS ELIZABETH JANE DAWSON + MR LEWIS MACDONALD DAWSON <DAWSON FAMILY A/C> 50,000 – ORDINARY SHARES 2,500,000 – UNLISTED OPTIONS, EXERCISE PRICE \$0.30, EXPIRY DATE 30 SEP 2024 2,000,000 – UNLISTED OPTIONS, EXERCISE PRICE \$0.65, EXPIRY DATE 03 JUN 2025
Class	ORDINARY SHARES & UNLISTED OPTIONS

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Number acquired	1,590,909 – ORDINARY SHARES
Number disposed	1,590,909 – OPTIONS EXERCISED 909,091 – OPTIONS CANCELLED IN LIEU OF PAYING OPTION EXERCISE PROCEEDS
Value/Consideration <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	Terms of options include a cashless exercise mechanism. 909,091 options have been cancelled equal to the value of exercise proceeds due (\$750,000) using the 15 day VWAP of \$0.825 at notice of exercise.
No. of securities held after change	MRS ELIZABETH JANE DAWSON + MR LEWIS MACDONALD DAWSON <DAWSON FAMILY A/C> 1,640,909 – ORDINARY SHARES 2,000,000 – UNLISTED OPTIONS, EXERCISE PRICE \$0.65, EXPIRY DATE 03 JUN 2025
Nature of change <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small>	EXERCISE OF OPTIONS

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	N/A
Interest acquired	N/A

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

Interest disposed	N/A
Value/Consideration <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	N/A
Interest after change	N/A

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	NO
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

⁺ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	ARGENICA THERAPEUTICS LIMITED
ABN	38 620 388 230

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	TERRY BUDGE
Date of last notice	25 FEBRUARY 2022

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	INDIRECT
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	CONTROLLER OF TRUSTEE AND BENEFICIARY
Date of change	8 AUGUST 2024
No. of securities held prior to change	T & L BUDGE HOLDINGS PTY LTD <T & L BUDGE SUPER FUND A/C> 487,520 – ORDINARY SHARES 500,000 – UNLISTED OPTIONS, EXERCISE PRICE \$0.30, EXPIRY DATE 30 SEP 2024
Class	ORDINARY SHARES & UNLISTED OPTIONS
Number acquired	318,182 – ORDINARY SHARES
Number disposed	318,182 – OPTIONS EXERCISED 181,818 – OPTIONS CANCELLED IN LIEU OF PAYING OPTION EXERCISE PROCEEDS

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Terms of options include a cashless exercise mechanism. 181,818 options have been cancelled equal to the value of exercise proceeds due (\$150,000) using the 15 day VWAP of \$0.825 at notice of exercise.
No. of securities held after change	T & L BUDGE HOLDINGS PTY LTD <T & L BUDGE SUPER FUND A/C> 805,702 – ORDINARY SHARES
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	EXERCISE OF OPTIONS

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

+ See chapter 19 for defined terms.

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	NO
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

⁺ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	ARGENICA THERAPEUTICS LIMITED
ABN	38 620 388 230

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	LIDDY MCCALL
Date of last notice	9 JUNE 2021

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	INDIRECT
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	CONTROLLER OF TRUSTEE AND BENEFICIARY
Date of change	8 AUGUST 2024
No. of securities held prior to change	STILLA PTY LTD <MCCHITE SUPERANNUATION FUND A/C> 125,000 – ORDINARY SHARES TOROHA PTY LTD <WHITE FAMILY A/C> 500,000 – UNLISTED OPTIONS, EXERCISE PRICE \$0.30, EXPIRY DATE 30 SEP 2024
Class	ORDINARY SHARES & UNLISTED OPTIONS
Number acquired	318,182 – ORDINARY SHARES

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Number disposed	318,182 – OPTIONS EXERCISED 181,818 – OPTIONS CANCELLED IN LIEU OF PAYING OPTION EXERCISE PROCEEDS
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Terms of options include a cashless exercise mechanism. 181,818 options have been cancelled equal to the value of exercise proceeds due (\$150,000) using the 15 day VWAP of \$0.825 at notice of exercise.
No. of securities held after change	STILLA PTY LTD <MCCHITE SUPERANNUATION FUND A/C> 125,000 – ORDINARY SHARES TOROHA PTY LTD <WHITE FAMILY A/C> 318,182 – ORDINARY SHARES
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	EXERCISE OF OPTIONS

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	NO
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

⁺ See chapter 19 for defined terms.